News Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
104.85 ^USD	+2.03%		+2.95%	+2.65%

01-22	Guardant Health Receives FDA Approval for Colorectal Cancer Diagnostic	MT
01-19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI

All News

02-12	Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open	PR
02-12	Single‑Reference Disclosures And The Motivation‑To‑Combine Requirement	AQ
02-03	Guardant Health to Participate in Upcoming Investor Conferences	BU
02-03	Largest Published Study of Molecular Residual Disease in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence after Surgery to Support Timely Treatment Decisions	AQ
02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
02-02	Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions	BU
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
01-29	Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026	BU
01-22	Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	CI
01-22	Guardant Health Receives FDA Approval for Colorectal Cancer Diagnostic	MT
01-22	Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	BU
01-19	Guardant Health announces multi-year strategic collaboration agreement with Merck	RE
01-19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI
01-19	Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	BU
01-15	Guardant Health : JP Morgan Healthcare Conference	PU
01-15	Guardant Health : Corporate Governance Guidelines (Corporate Governance Guidelines FINAL as of 10 22 2025)	PU
01-15	Guardant Health : Compensation Committee Charter (Compensation Committee Charter FINAL as of 10 22 2025)	PU
01-13	Guardant Health, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
01-12	Guardant Health shares up 2.4% after preliminary Q4 revenue beats estimates	RE
01-12	Independence, Under Review
01-12	Guardant Health Sees 39% Rise in Q4 Preliminary Revenue	MT
01-11	Guardant Health Q4 total revenue of approx $280 million	RE
01-11	Guardant Health : Announces Preliminary Fourth Quarter and Full Year 2025 Results	PU
01-11	Guardant Health, Inc. Provides Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-11	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

All News

Filters